Incretin Atlas › Trials › ACHIEVE-1
ACHIEVE-1
Orforglipron · t2d
Design
- Molecule(s)
- Orforglipron
- Population
- t2d
- Official title
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2023-08 → 2025-04
- Participants
- 559
- Duration
- 40 weeks
- Registry
- NCT05971940
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| orforglipron 36 mg | t2d | 40 | 559 | −7.9 % vs −1.6 % Δ −6.3 pp | −7.6 % vs −1.7 % Δ −5.9 pp | −1.5 vs −0.4 | 7.8 vs 1.4 | 9.9 vs 7.2 | 16.3 vs 2.2 | 14.2 vs 1.4 | 2.8 vs 3.6 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- orforglipron 36 mg: Any discontinuation = 100 − % continuing the drug to week 40.
Verbatim quotes from the source (8)
- orforglipron 36 mg · weight_eff · Figure 2B (end-of-curve labels, efficacy estimand; garbled o
−4.7% (−4.4 kg) −7.9% (−7.3 kg) −1.6% (−1.3 kg) −6.1% (−5.5 kg)
- orforglipron 36 mg · weight_tp · Results, End Points paragraph; Figure 2A
−7.6% (95% CI, −8.8 to −6.4) with the 36-mg dose
- orforglipron 36 mg · ae_dc · Table 2
Adverse event leading to discontinuation of orforglipron or placebo 8 (5.6) 6 (4.4) 11 (7.8) 2 (1.4) 27 (4.8)
- orforglipron 36 mg · nausea · Table 2
Nausea 18 (12.6) 25 (18.2) 23 (16.3) 3 (2.2) 69 (12.3)
- orforglipron 36 mg · vomiting · Table 2
Vomiting 7 (4.9) 9 (6.6) 20 (14.2) 2 (1.4) 38 (6.8)
- orforglipron 36 mg · sae · Table 2
Any serious adverse event 8 (5.6) 7 (5.1) 4 (2.8) 5 (3.6) 24 (4.3)
- orforglipron 36 mg · hba1c · Abstract; Results, End Points
−1.48 percentage points with the 36-mg dose
- orforglipron 36 mg · disc_any · Results, Participants
and 504 par- ticipants (90.2%; 129 in the 3-mg group, 120 in the 12-mg group, 127 in the 36-mg group, and 128 in the placebo group) continued to receive orforglipron or placebo throughout the 40-week
Primary sources
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1). ClinicalTrials.gov identifier NCT05971940. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05971940
- Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065-1076. PMID: 40544435.
How to cite this page
Medical Adviser's Group. Incretin Atlas: ACHIEVE-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.